CLOV vs OCGN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

CLOV

45.8
AI Score
VS
CLOV Wins

OCGN

34.8
AI Score

Investment Advisor Scores

CLOV

46score
Recommendation
HOLD

OCGN

35score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CLOV OCGN Winner
Revenue 2.25B 4.97M CLOV
Net Income 61.77M -47.65M CLOV
Net Margin 2.7% -958.2% CLOV
Operating Income 61.77M -52.03M CLOV
ROE 15.8% 269.5% OCGN
ROA 8.2% -44.1% CLOV
Total Assets 753.68M 108.06M CLOV
Current Ratio 1.55 0.77 CLOV
Free Cash Flow 201.03M -49.91M CLOV

Relative Price Performance (Last 90 Days)

CLOV 1M: +3.3% · 3M: +10.7% OCGN 1M: +8.5% · 3M: -28.9%

Current Technical Phase

CLOV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.8% over 20 days), RSI 60

RSI (14): 59.7 · Price: $4.97

OCGN

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 58

RSI (14): 57.8 · Price: $0.96

Fundamentals Snapshot

Metric CLOV OCGN
Market Cap — —
Forward P/E 27.6 -5.3
Trailing P/E 493.0 —
Revenue (TTM) — —
Revenue Growth 0.5% 0.1%
Gross Margin 0.2% -8.4%
Operating Margin 0.0% -9.1%
EPS 0.01 -0.20
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CLOV is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.